ArticleGeneral thoracic and cardiovascular surgery2026
Early major adverse kidney events after lung transplantation: risk of chronic kidney disease and prognostic impact.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRenal dysfunction, including acute kidney injury (AKI) and chronic kidney disease (CKD), is a major complication following lung transplantation (LT) and is associated with increased morbidity and mortality. This study aims to evaluate the clinical significance of AKI in relation to the development of post-LT CKD and poor prognosis.
methodsAmong 133 patients who underwent LT, 116 were included in the analysis. AKI was defined according to the Kidney Disease Improving Global Outcomes criteria. AKI was classified into early AKI (E-AKI), occurring within a few hours to one week postoperatively, and late AKI (L-AKI), occurring between one week and one month after LT. The Major Adverse Kidney Event within 30 days following LT (MAKE30)-a composite outcome that includes all-cause mortality, new renal replacement therapy, or persistent renal dysfunction-was also used in this study. Univariate and multivariate analyses were conducted to identify factors associated with the development of CKD. Overall survival (OS) was analyzed using the Kaplan-Meier method.
resultsThe proportions of patients who developed E-AKI, L-AKI, MAKE30, and CKD were 73%, 31%, 15%, and 46%, respectively. Multivariate analysis identified older age and the occurrence of MAKE30 as independent predictors of post-LT CKD. Notably, all recipients aged 50 years or older who experienced either L-AKI or MAKE30 subsequently developed CKD. In addition, the incidence of MAKE30 was marginally correlated with reduced OS.
conclusionThe occurrence of L-AKI and MAKE30 following LT is associated with the development of CKD and MAKE30 also has a negative impact on OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.